8-K: Trevi Therapeutics Appoints David Hastings as New CFO
Management Change
Trevi Therapeutics, Inc. announced the appointment of David Hastings, a seasoned biopharmaceutical executive, as its new Chief Financial Officer, effective January 6, 2026.
Summary
- Trevi Therapeutics, Inc. has appointed David Hastings as its Chief Financial Officer and principal financial officer.
- Mr. Hastings' appointment is effective January 6, 2026.
- He will receive an annualized base salary of $522,000 and an annual incentive bonus of up to 40% of his base salary.
- Mr. Hastings will be granted an option to purchase 375,000 shares of common stock, vesting 25% on the first anniversary and 1/48th monthly thereafter.
- He will also be eligible for separation benefits under the company's Executive Separation Benefits and Retention Plan.
- The company will enter into a standard indemnification agreement with Mr. Hastings.
Sentiment
Score: 7
Explanation: The appointment of a highly experienced CFO with a strong background in public biopharmaceutical companies is generally a positive development, signaling stability and expertise in financial management. The compensation package, including stock options, is standard for an executive of this caliber.
Positives
- David Hastings brings extensive experience as a Chief Financial Officer from several publicly held biopharmaceutical companies, including Arbutus Biopharma Corporation, Unilife Corporation, Incyte Corporation, and ArQule Inc.
- His current role as a board member and chair of the audit committee for Scynexis, Inc. demonstrates strong corporate governance and financial oversight expertise.
Risks
- The company's standard indemnification agreement with Mr. Hastings may require it to cover significant expenses, including attorneys' fees, judgments, fines, and settlement amounts, incurred by him in actions arising from his service.
Future Outlook
The filing does not provide specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the appointment of a new CFO.
Management Comments
- The company announced the hiring of David Hastings to serve as its Chief Financial Officer and principal financial officer.
Industry Context
The appointment of a new Chief Financial Officer with extensive experience in publicly traded biopharmaceutical companies is a common occurrence in the dynamic and capital-intensive biotechnology sector, where strong financial leadership is crucial for managing R&D, clinical trials, and potential commercialization efforts.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer and Principal Financial Officer | David Hastings | January 6, 2026 | New hire |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Structure | Establishment of an annualized base salary of $522,000, an annual incentive bonus of up to 40% of base salary, eligibility for separation benefits, and a grant of 375,000 stock options for the new CFO. | January 6, 2026 | Aligns executive incentives with company performance and shareholder value through equity grants and performance-based bonuses. |
| Indemnification Agreement | The company will enter into its standard form of indemnification agreement with the new CFO, potentially requiring the company to indemnify him for certain expenses. | January 6, 2026 | Provides protection for the executive against liabilities incurred during service, which is standard practice but represents a potential financial obligation for the company. |
Stakeholder Impact
- Shareholders: The appointment of an experienced CFO may enhance investor confidence and provide stability in financial leadership. The stock option grant could lead to minor dilution over time.
- Employees: A new CFO can bring changes to financial operations and strategic direction, potentially impacting various departments.
- Creditors: Strong financial leadership can improve the company's perceived creditworthiness and financial management.
Next Steps
- The Offer Letter agreement with Mr. Hastings will be filed as an exhibit to the company's Annual Report on Form 10-K for the year ended December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 2003 | David Hastings began serving as Chief Financial Officer and Executive Vice President of Incyte Corporation. |
| 2014 | David Hastings concluded his tenure as Chief Financial Officer and Executive Vice President of Incyte Corporation. |
| 2015 | David Hastings began serving as Senior Vice President and Chief Financial Officer at Unilife Corporation. |
| 2017 | David Hastings concluded his tenure as Senior Vice President and Chief Financial Officer at Unilife Corporation. |
| June 2018 | David Hastings began serving as Chief Financial Officer of Arbutus Biopharma Corporation. |
| September 24, 2019 | Company's Current Report on Form 8-K (File No. 001-38886) filed with the SEC, which included the Executive Separation Benefits and Retention Plan as Exhibit 10.1. |
| March 2025 | David Hastings concluded his tenure as Chief Financial Officer of Arbutus Biopharma Corporation. |
| December 1, 2025 | Date of earliest event reported in the 8-K filing. |
| December 4, 2025 | Company announced the hiring of David Hastings. |
| December 5, 2025 | Date of filing the 8-K report. |
| January 6, 2026 | Effective date of David Hastings' employment as Chief Financial Officer. |
| December 31, 2025 | Year-end for which the Offer Letter will be filed as an exhibit to the Annual Report on Form 10-K. |
Keywords
Trevi Therapeutics, TRVI, Chief Financial Officer, CFO appointment, David Hastings, biopharmaceutical, executive compensation, stock options, corporate governance, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.